Cvrx, INC 8-K filings

CVRx, Inc. announced the departure of its Chief Revenue Officer, Robert John, and the appointment of Paul Verrastro as Interim Head of Sales.

CVRx, Inc. reports the resignation of CFO Jared Oasheim, detailing his transition plan, consulting role, and compensation package.

CVRx, Inc. reported voting results from its 2026 annual meeting of stockholders, including the election of directors and ratification of its independent auditor.

CVRx, Inc. announced first quarter 2026 financial and operating results, highlighting a 20% increase in total revenue to $14.8 million and a 22% rise in U.S. revenue to $13.7 million, driven by expanded sales territories and increased physician awareness of its Barostim therapy.

CVRx, Inc. announced preliminary Q1 2026 financial results showing approximately 20% revenue growth, improved gross margins, and positive early data on prior authorization approval rates.

CVRx, Inc. approved performance stock units for executive officers tied to a confidential cumulative revenue goal for fiscal years 2026-2027.

CVRx, Inc. announced its fourth quarter and full year 2025 financial results, highlighting revenue growth and the initiation of the landmark BENEFIT-HF trial.

CVRx, Inc. has entered into an Open Market Sale Agreement with Jefferies LLC to offer and sell up to $50.0 million of its common stock.

CVRx, Inc. announced preliminary Q4 and full-year 2025 revenues, issued 2026 guidance, amended its debt facility to increase available capital by $50 million, and provided an update on its BENEFIT-HF trial.

CVRx, Inc. reported a 10% increase in third-quarter 2025 total revenue to $14.7 million and updated its full-year guidance with higher revenue and gross margin expectations.

CVRx, Inc. announced its second quarter 2025 financial results, reporting a 15% revenue increase and the appointment of Brent Binkowski as Chief Operating Officer.

CVRx, Inc. announced the successful election of two Class I directors and the ratification of Grant Thornton LLP as its independent registered public accounting firm at its 2025 annual meeting of stockholders.

CVRx, Inc. announced a 15% increase in total revenue for Q1 2025, primarily driven by growth in its U.S. Heart Failure business.

CVRx announces preliminary Q1 2025 revenue of approximately $12.3 million, a 15% increase year-over-year, but below internal expectations due to slower sales representative ramp-up and seasonal softness.

CVRx announces a 36% increase in fourth-quarter revenue and a 31% increase in full-year revenue for 2024, fueled by significant growth in the U.S. heart failure market.

CVRx reports a 35% increase in fourth-quarter revenue and a 30% increase in full-year revenue for 2024, alongside a positive outlook for 2025.

CVRx, Inc. announced that the Barostim procedure has been assigned to New Technology Ambulatory Payment Classification (APC) 1580 by the Centers for Medicare and Medicaid Services, with a payment of approximately $45,000 continuing in 2025.

CVRx announced a 27% increase in total revenue for the third quarter of 2024, driven by a 30% increase in U.S. heart failure revenue and a 31% increase in active implanting centers.

CVRx, Inc. has completed the final $20 million draw from its term loan facility with Innovatus Life Sciences Fund I, LP, bringing the total outstanding loan amount to $50 million.

CVRx, Inc. has appointed Kevin Ballinger and Mitch Hill as new independent directors, while Ali Behbahani has resigned from the board, leading to an increase in the board size to seven members.

CVRx announced a 24% increase in total revenue for the second quarter of 2024, primarily driven by a 27% growth in its U.S. heart failure business.

CVRx, Inc. stockholders approved an amendment to the company's charter to allow for officer exculpation, among other matters, at the 2024 annual meeting.

CVRx reaffirmed its full-year 2024 financial guidance and second-quarter revenue expectations during a presentation at the William Blair 44th Annual Growth Stock Conference.

CVRx, Inc. announced a 35% increase in total revenue for the first quarter of 2024, driven by a 43% surge in U.S. heart failure revenue, despite facing some commercial execution challenges.

CVRx has appointed Kevin Hykes as its new President and CEO, succeeding Nadim Yared, effective February 12, 2024.

CVRx reported a 75% increase in total revenue for 2023, driven by strong adoption of its Barostim therapy for heart failure.